Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin

American Journal of Pathology

Volumn 177, Issue 2, 2010, Pages 1004-1016

  Cueni, Leah N ^a   Hegyi, Ivan ^b   Shin, Jay W ^a   Albinger Hegyi, Andrea ^c   Gruber, Silke ^d   Kunstfeld, Rainer ^d   Moch, Holger ^c   Detmar, Michael ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; PODOPLANIN; TENASCIN; VILLIN;

ADULT; ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; LYMPHOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 77957284078     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090703     Document Type: Article

References (55)

1. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, Kerjaschki D: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997, 151:1141-1152
2. Zimmer G, Oeffner F, Von Messling V, Tschernig T, Groness HJ, Klenk HD, Herrler G: Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium. Biochem J 1999, 341:277-284
3. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999, 154:385-394
4. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G, Detmar M: T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003, 22:3546-3556
5. Ramirez MI, Millien G, Hinds A, Cao Y, Seldin DC, Williams MC: T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Dev Biol 2003, 256:61-72
6. Gandarillas A, Scholl FG, Benito N, Gamallo C, Quintanilla M: Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog 1997, 20:10-18
7. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005, 166:913-921
8. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M: Enhanced expression of aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005, 26:195-200
9. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, Quintanilla M: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005, 113:899-910
10. Kimura N, Kimura I: Podoplanin as a marker for mesothelioma. Pathol Int 2005, 55:83-86
11. Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M: Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 2006, 448:493-499
12. Watanabe M, Okochi E, Sugimoto Y, Tsuruo T: Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies. Cancer Res 1988, 48:6411-6416
13. Watanabe M, Sugimoto Y, Tsuruo T: Expression of a Mr 41,000 glycoprotein associated with thrombin-independent platelet aggregation in high metastatic variants of murine B16 melanoma. Cancer Res 1990, 50:6657-6662
14. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006, 111:483-488
15. Raica M, Ribatti D, Mogoanta L, Cimpean AM, Ioanovici S: Podoplanin expression in advanced-stage gastric carcinoma and prognostic value of lymphatic microvessel density. Neoplasma 2008, 55:455-460
16. Scholl FG, Gamallo C, Vilaro S, Quintanilla M: Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci 1999, 112:4601-4613
17. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006, 9:261-272
18. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial- mesenchymal transition. J Cell Sci 2006, 119:4541-4553
19. Scholl FG, Gamallo C, Quintanilla M: Ectopic expression of PA2.26 antigen in epidermal keratinocytes leads to destabilization of adherens junctions and malignant progression. Lab Invest 2000, 80:1749-1759
20. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, Tsuruo T: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003, 278:51599-51605
21. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T, Fujita N: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007, 170:1337-1347
22. Shin JW, Huggenberger R, Detmar M: Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 2008, 112:2318-2326
23. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M: Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005, 24:2885-2895
24. Brack SS, Silacci M, Birchler M, Neri D: Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006, 12:3200-3208
25. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847
26. Albinger-Hegyi A, Stoeckli SJ, Schmid S, Storz M, lotzova G, Probst-Hensch NM, Rehrauer H, Tinguely M, Moch H, Hegyi I: Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer 2010, 126:2653-2662
27. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A: PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003, 13:2129-2141
28. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, Bagnato A: Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000, 157:1703-1711
29. Rosano L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A: Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 2001, 61:8340-8346
30. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415
31. Wulfing P, Kersting C, Tio J, Fischer RJ, Wulfing C, Poremba C, Diallo R, Bocker W, Kiesel L: Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 2004, 10:2393-2400
32. Orend G, Chiquet-Ehrismann R: Tenascin-C induced signaling in cancer. Cancer Lett 2006, 244:143-163
33. Khurana S, George SP: Regulation of cell structure and function by actin-binding proteins: villin's perspective. FEBS Lett 2008, 582:2128-2139
34. Ferlito A, Rinaldo A, Robbins KT, Leemans CR, Shah JP, Shaha AR, Andersen PE, Kowalski LP, Pellitteri PK, Clayman GL, Rogers SN, Medina JE, Byers RM: Changing concepts in the surgical management of the cervical node metastasis. Oral Oncol 2003, 39:429-435
35. Chuang WY, Yeh CJ, Wu YC, Chao YK, Liu YH, Tseng CK, Chang HK, Liu HP, Hsueh C: Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma. Histol Histopathol 2009, 24:1021-1027
36. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L: Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008, 26:354-360
37. Rahadiani N, Ikeda JI, Makino T, Tian T, Qiu Y, Mamat S, Wang Y, Doki Y, Aozasa K, Morii E: Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann Surg Oncol 2010, 17:1311-1323
38. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006, 107:563-569
39. Louvet-Vallee S: ERM proteins: from cellular architecture to cell signaling. Biol Cell 2000, 92:305-316
40. Friederich E, Huet C, Arpin M, Louvard D: Villin induces microvilli growth and actin redistribution in transfected fibroblasts. Cell 1989, 59:461-475
41. Tomar A, Wang Y, Kumar N, George S, Ceacareanu B, Hassid A, Chapman KE, Aryal AM, Waters CM, Khurana S: Regulation of cell motility by tyrosine phosphorylated villin. Mol Biol Cell 2004, 15:4807-4817
42. Wang Y, Tomar A, George SP, Khurana S: Obligatory role for phospholipase C-gamma(1) in villin-induced epithelial cell migration. Am J Physiol Cell Physiol 2007, 292:C1775-C1786
43. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002, 38:2362-2370
44. Ishihara A, Yoshida T, Tamaki H, Sakakura T: Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1995, 1:1035-1041
45. Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S, Nakajima Y: Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001, 92:1419-1426
46. Juhasz A, Bardos H, Repassy G, Adany R: Characteristic distribution patterns of tenascin in laryngeal and hypopharyngeal cancers. Laryngoscope 2000, 110:84-92
47. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M: VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007, 109:1010-1017
48. Spinella F, Garrafa E, Di Castro V, Rosano L, Nicotra MR, Caruso A, Natali PG, Bagnato A: Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res 2009, 69:2669-2676
49. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732-735
50. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR: A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 2004, 64:2461-2468
51. Hagemann T, Binder C, Binder L, Pukrop T, Trumper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol 2005, 24:766-776
52. Hill CS, Wynne J, Treisman R: The Rho family GTPases RhoA. Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell 1995, 81:1159-1170
53. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS: The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 2004, 14:29-41
54. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC: Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins Genes Dev 1997, 11:463-475
55. Shephard P, Martin G, Smola-Hess S, Brunner G, Krieg T, Smola H: Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol 2004, 164:2055-2066